Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

• Status: Completed
• Trial end date: 2018-07-31
• Target enrollment: 0
• Participant gender: Male

Summary

To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Clarus Therapeutics, Inc.
• Collaborator: Celerion; Syneos Health; ARUP Laboratories
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

Subjects were required to meet all of the following criteria in order to be eligible for the study:

1. Male (gender at birth) 18 to 65 years of age, inclusive, and legally able to give informed consent, as applicable by law. The percentage of non-Hispanic and Hispanic men was specified to be approximately ≥ 70% and ≤ 30%, respectively.

2. Adequate venous access in the left or right arm to allow collection of a number of blood samples via a venous cannula or needle sticks

3. Naïve to androgen-replacement therapy

4. Willing to consume the entire protocol-specified breakfast and dinner meals

5. Average screening systolic blood pressure < 140 mmHg and/or diastolic blood pressure < 90 mmHg

6. Voluntarily gave written informed consent to participate in this study -

Exclusion Criteria:

Subjects who met any of the following criteria were not eligible for participation in this study:

1. History of hypertension or taking anti-hypertensive medications

2. Intercurrent disease deemed clinically significant, in the opinion of the Investigator, of any type; in particular, liver, kidney, uncontrolled or poorly controlled heart disease, including congestive heart failure, coronary heart disease, heart attack or cerebrovascular accident in prior 6 months, or psychiatric-illness, including severe depression

3. Electrocardiogram which Principal Investigator, or designate, believed was clinically significantly abnormal

4. Intercurrent process or disease which could have impacted the absorption of JATENZO, in particular vomiting, nausea, diarrhea, or inflammatory bowel disease

5. Current use of the following groups of drugs that affect testosterone levels, testosterone metabolism, or levels of testosterone metabolites, namely antiandrogens, 5 alpha reductase inhibitors (eg, dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone hydrochloride, buprenorphine hydrochloride), or human growth hormone

6. History of or was currently being evaluated for breast or prostate cancer

7. Prostate specific antigen above the upper limit of normal

8. Positive test for antibodies to human immunodeficiency virus type 1 or 2, hepatitis B surface antigen, or antibodies to hepatitis C virus at the Screening visit

9. Positive urine drug test at the Screening visit

10. Current treatment with oral lipase inhibitors (eg, orlistat [Xenical]), bile acid-binding resins (eg, cholestyramine [Questran], colestipol [Colestid]), fibric acid derivatives (eg, clofibrate [Atromid-X], gemfibrozil [Lopid]), and probucol (Lorelco).

11. Smokers who were unable to refrain from smoking during the confinement period required in this study

12. Current evidence of or history of abuse of alcohol or any drug substance within the previous 2 years

13. Receipt of any drug as part of a research study within 30 days of initial dose administration in this study

14. Blood donation (usually 550 mL) within the 12-week period before the initial study drug dose

15. Hematocrit < 35% or > 50%

16. Body mass index ≥ 31 kg/m2 -